Corbus Pharmaceuticals Holdings, Inc. 是一家臨床階段製藥公司,專注於開發及商業化針對內源性大麻素系統的新型療法,應用於自身免疫、纖維化及癌症領域。公司總部位於麻薩諸塞州諾伍德。
財務指標
營業收入
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
營業支出
2026-06-30
$36.19M
2026-03-31
$24.25M
2025-12-31
$21.96M
2025-09-30
$24.41M
淨利潤
2026-06-30
-$35.03M
2026-03-31
-$22.96M
2025-12-31
-$20.55M
2025-09-30
-$23.34M
淨利潤率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
每股收益
2026-06-30
$-1.81
2026-03-31
$-1.23
2025-12-31
$-1.25
2025-09-30
$-1.90
息稅折舊攤銷前利潤
2026-06-30
-$34.98M
2026-03-31
-$22.92M
2025-12-31
-$20.5M
2025-09-30
-$23.29M
有效稅率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
項目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
營業收入
$0
$0
$0
$0
營業支出
$36.19M
$24.25M
$21.96M
$24.41M
淨利潤
-$35.03M
-$22.96M
-$20.55M
-$23.34M
淨利潤率
--
--
--
--
每股收益
$-1.81
$-1.23
$-1.25
$-1.90
息稅折舊攤銷前利潤
-$34.98M
-$22.92M
-$20.5M
-$23.29M
有效稅率
--
--
--
--
常見問題
CRBP is the ticker symbol for Corbus Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company. Its stock represents ownership in a company focused on developing novel therapeutics that target the endocannabinoid system and other pathways to treat inflammatory and fibrotic diseases. Shares trade on the Nasdaq Capital Market. The company's value is closely tied to the progress of its drug candidates through clinical trials.
Clinical trial results for Corbus Pharmaceuticals' drug candidates are a primary driver of CRBP stock, as positive or negative data can sharply move the share price. Regulatory decisions from the FDA, partnership announcements, and changes in the competitive landscape also matter. Additionally, broader market conditions, investor sentiment toward small-cap biotech, and the company's cash position can influence the stock. Because CRBP is a clinical-stage company, sentiment often hinges on pipeline progress.
The 52-week range shows the lowest and highest prices at which CRBP stock has traded over the past year. This range helps investors gauge recent volatility and where the current price sits relative to its annual high and low. For the latest 52-week range for CRBP, please refer to the current data displayed on this page, as the figures change with daily trading.
Valuing CRBP is unconventional because Corbus Pharmaceuticals is a clinical-stage biotech with no approved products, so traditional metrics like P/E ratios are not useful. Instead, investors often assess the company's cash position, burn rate, and the perceived potential of its pipeline. Analysts may use risk-adjusted net present value models or compare market capitalization to projected peak sales of drug candidates. Ongoing clinical milestones are key to valuation.
To buy CRBP stock, you need a brokerage account that offers access to Nasdaq-listed securities. Most online brokers allow you to search for the ticker CRBP and place a market or limit order during regular trading hours. Some brokers also support extended-hours trading and fractional shares, though availability varies. Ensure you understand order types and any associated fees before trading.
Earnings information for CRBP is typically reported quarterly by Corbus Pharmaceuticals through press releases and SEC filings such as 10-Q and 10-K reports. These documents are available on the company's investor relations website and the SEC's EDGAR database. The latest earnings details, including net loss, cash position, and research expenses, can also be found on this page or through major financial data providers.